Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.69 USD
+0.08 (4.97%)
Updated Oct 4, 2024 03:59 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Lexicon Pharmaceuticals (LXRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.20 | $10.00 | $2.00 | 266.86% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Lexicon Pharmaceuticals comes to $6.20. The forecasts range from a low of $2.00 to a high of $10.00. The average price target represents an increase of 266.86% from the last closing price of $1.69.
Analyst Price Targets (5 )
Broker Rating
Lexicon Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy, representing 66.67% of all recommendations. A month ago, Strong Buy represented 66.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.67 | 1.67 | 1.67 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/27/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
8/13/2024 | SVB Securities | Roanna Ruiz | Strong Buy | Strong Buy |
5/30/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
4/11/2024 | Needham & Company | Joseph R Stringer | Hold | Hold |
3/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/1/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 6 |
Average Target Price | $6.20 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -0.16 |
LXRX FAQs
Lexicon Pharmaceuticals, Inc. (LXRX) currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for Lexicon Pharmaceuticals, Inc. (LXRX) is $6.20. The current on short-term price targets is based on 4 reports.
The forecasts for Lexicon Pharmaceuticals, Inc. (LXRX) range from a low of $2 to a high of $10. The average price target represents a increase of $266.86 from the last closing price of $1.69.
The current UPSIDE for Lexicon Pharmaceuticals, Inc. (LXRX) is 266.86%
Based on short-term price targets offered by five analysts, the average price target for Lexicon Pharmaceuticals comes to $6.20. The forecasts range from a low of $2.00 to a high of $10.00. The average price target represents an increase of 266.86% from the last closing price of $1.69.